You searched for
Tag:
Research
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07/07/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05/05/2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12/04/2023
2022 for Chiesi: The Group’s international growth continues
05/04/2023
Restore to Impact - The next healthcare landmark for innovation and future-oriented competencies
01/03/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
24/02/2023
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
04/12/2022
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
18/10/2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27/07/2022
Solidarity actions to support the people affected by the war
08/04/2022
Chiesi Group continues to grow
31/03/2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
16/12/2021
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
14/12/2021
CLIMATE CHANGE – A MAJOR THREAT TO RESPIRATORY HEALTH IN EUROPE SAYS NEW REPORT FROM ECONOMIST INTELLIGENCE UNIT
07/09/2021
Chiesi Group receives European Marketing Authorisation for its triple combination therapy inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) in extrafine fixed formulation delivered through NEXThaler, for the treatment of moderate to severe COPD
21/04/2021